Skip to main navigation Skip to search Skip to main content

Patient-reported outcomes and metabolic changes in men treated with enzalutamide or abiraterone acetate plus prednisone for metastatic castration-resistant prostate cancer

Original languageEnglish
Publication statusPublished - 2021

Cite this